Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells
August 14, 2020
The trial, Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients with Severe Crohn’s Disease is based on a novel, reduced intensity conditioning regimen, followed by autologous stem cell transplantation. Potentially, autoreactive lymphocytes will be depleted in the stem cell laboratory by CD34 selection following stem cell mobilization and collection.
We anticipate that after lymphocyte depleted stem cell infusion, a normal immune system will reconstitute without recurrence of autoimmunity or to reduce disease burden even if recurrence was to take place eventually.
In addition, we propose this conditioning regimen is a safer strategy from a cardiopulmonary, urinary perspective compared to the published work from other centers, nevertheless, is paired with more intense immune suppression to lead to improved symptoms and prevent or delay Crohn’s disease recurrence.
Trial Eligibility
This study is open to children and adults between the ages of 10-60 years. For additional requirements and criteria please visit visit the NIH Clinical Trials website.
Start Date: December 5, 2017
Learn more about this trial on its clinicaltrials.gov page or contact Shawna McIntyre, BSN, RN at mcintyresm@upmc.edu.
Project Team
Principal Investigator:
Paul Szabolcs, MD
Team Members:
David Binion, MD
Annie Im, MD
David Keljo, MD
Interested in receiving specialty-specific information? Register for UPMC Physician Resources to get emerging research, clinical updates, and free CME straight to your inbox.
